The STADA delisting offer announced in 2018 was a cash offer by Nidda Healthcare GmbH to acquire shares in STADA Arzneimittel AG that it did not already hold. The offer was closely linked to a proposed withdrawal of STADA shares from regulated trading venues. For shareholders, the document set out both the price and the steps required to tender shares; for readers assessing corporate ownership changes, it illustrates how an acquisition offer can be used to support a delisting process.
What the STADA delisting offer proposed
Nidda Healthcare offered €81.73 in cash for each eligible STADA share. The offer covered all STADA shares not directly held by Nidda Healthcare and included the associated rights existing at settlement, including dividend entitlements. It was addressed to all STADA shareholders and conducted under German securities rules, including the German Securities Acquisition and Takeover Act (WpÜG) and the requirements of the German Stock Exchange Act (BörsG).
The offer period ran from 11 October to 8 November 2018, ending at midnight Frankfurt time, equivalent to 18:00 in New York. The offer document stated that completion was not subject to conditions. It also set out that the offer was intended to enable the delisting of STADA shares; it did not itself establish that the delisting had already occurred.
How the proposed delisting was structured
STADA shares were admitted to the regulated markets of the Frankfurt Stock Exchange and the Düsseldorf Stock Exchange. They were also traded on Xetra and included in several other trading venues. Nidda Healthcare said it had instructed STADA’s management board to apply to revoke the shares’ admission to the regulated markets shortly before the offer period ended, following coordination between the parties.
The instruction also covered taking reasonable measures, where possible and legally permissible, to end the inclusion of STADA shares on other organized trading platforms, including certain open-market venues. The document separately discussed STADA’s bonds, including the possibility of seeking withdrawal of their admission to the regulated market of the Luxembourg Stock Exchange. These were distinct securities and procedures from the offer for STADA shares.
A delisting changes where a company’s shares are admitted to trading; it is not, by itself, a statement that the company will stop operating. In this case, the offer document described the proposed exchange-listing changes and the cash purchase offer as related parts of the plan.
How shareholders could accept the offer
Shareholders wishing to tender had to submit an acceptance declaration to their custodian bank during the acceptance period. The tender became effective only after the relevant shares were transferred into the designated tendered-share category, identified by a separate ISIN. The shares remained in the shareholder’s securities account until settlement, but tendered shares were not traded on the exchange.
For shareholders holding shares in a German securities account, the offer document said acceptance would generally be free of custodian-bank fees, apart from costs associated with transmitting the acceptance declaration. Additional charges from foreign service providers, as well as applicable foreign taxes or transaction costs, could still be borne by the shareholder.
Payment was to be made promptly after settlement, and no later than the twelfth banking day after publication of the offer results following the acceptance period. The offer document also described circumstances that could extend the deadline, such as a change to the offer, a competing offer or the convening of a STADA shareholders’ meeting during the acceptance period.
Important considerations for shareholders
Shareholders who did not accept the offer would remain invested in STADA, but the document highlighted potential consequences of a successful delisting. These included a possible reduction in the free float and in the liquidity of STADA shares. It also cautioned that the share price could be adversely affected after the offer or in connection with the proposed delisting.
Those considerations are particularly relevant when comparing a fixed cash offer with continued share ownership. The offer price provided a defined payment for shareholders who tendered, while those who retained their shares would remain exposed to the trading and liquidity conditions described in the offer document. The document did not guarantee a particular future share price or trading outcome.
American Depositary Receipt holders faced an additional procedural step: STADA ADRs could not be tendered directly. Holders would first need to exchange their ADRs for STADA shares before accepting the offer. The document also warned shareholders outside Germany, the European Union, the European Economic Area and the United States to consider local legal restrictions. Tax consequences could vary by shareholder and jurisdiction, so the offer document recommended obtaining independent tax advice.
What the offer document does—and does not—establish
The offer was published after review by Germany’s Federal Financial Supervisory Authority (BaFin), which permitted publication of the German-language document on 11 October 2018. That regulatory review related to the offer document under German law; the document stated that it had not been reviewed or approved by regulators outside Germany.
The document also described Nidda Healthcare’s ownership structure, including the involvement of investment groups Bain Capital and Cinven, and explained that Nidda Healthcare had previously acquired control of STADA through a voluntary takeover offer. These details provide context for the bidder and the proposed transaction, but they do not change the stated terms of the €81.73-per-share delisting offer.
Practical takeaway
The 2018 STADA proposal combined a cash acquisition offer with a planned withdrawal of the company’s shares from regulated markets. Shareholders had to weigh the stated cash price against the risks of remaining invested if trading venues changed, while also following the custodian-bank and tendering procedures. Because the offer document describes a historical proposal rather than confirming its final outcome, it should be read as a record of the announced terms and intended process—not as evidence of what ultimately happened.